Title |
Effect of cyp1a1, cyp1b1 and cyp2c gene polymorphisms on doxorubicin and paclitaxel |
Authors |
Rashmi A. Gudur1,*, Suresh J. Bhosale1, Anand K. Gudur1 & Kailas D. Datkhile2 |
Affiliation |
1Department of Oncology, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Satara - 415 539, Maharashtra, India; 2Department of Molecular Biology and Genetics, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Satara - 415 539, Maharashtra, India; *Corresponding author |
|
Rashmi A. Gudur - E - mail: rashmiagudur@gmail.com
|
Article Type |
Research Article
|
Date |
Received October 1, 2024; Revised October 31, 2024; Accepted October 31, 2024, Published October 31, 2024 |
Abstract |
The genes encoding metabolizing cytochrome P450 enzyme are studied for their importance in cancer susceptibility. Therefore, it is of interest to identify the correlation of CYP1A, CYP1B and CYP2C gene polymorphisms (G-PMP) on drug response (DG-RS) and toxicity reactions in Indian population. 200 breast cancer (BC) patients received Doxorubicin (DXR) and paclitaxel (PCX) chemotherapy (CTP). Further, CTP induced hematological (HEM) and none (N)-HEM toxicity (TC) reactions were recorded. We found that, the univariate logistic regression analysis showed negative association of CYP1B1 (4326 C>G) G-PMP with microsites (OR=0.14, 95% CI: 0.03-0.54; p=0.004) in BC patients treated with DXR. Thus, protective effect of CYP1B1-PMP with DXR and PCX based CTP induced N-HEM-TC and CYP2C9-PMP with PCX induced body ache and CYP1A1-PMP with peripheral neuropathy in breast cancer patients. |
Keywords |
Breast cancer, G-PMP, CYP1A1, CYP1B1, CYP2C, chemotherapy, toxicity
|
Citation |
Gudur et al. Bioinformation 20(10): 1244-1250 (2024)
|
Edited by |
Neelam Goyal & Shruti Dabi
|
ISSN |
0973-2063
|
Publisher |
|
License |
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
|
|